<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03632915</url>
  </required_header>
  <id_info>
    <org_study_id>HP-00066222</org_study_id>
    <nct_id>NCT03632915</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antiepileptics in Patients on CRRT</brief_title>
  <acronym>PADRE</acronym>
  <official_title>Pharmacokinetics of Antiepileptic Drugs in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Maryland, Baltimore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Maryland, Baltimore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure levels of any of the following AEDs (levetiracetam,&#xD;
      phenobarbital, phenytoin, ketamine, valproic acid, lacosamide) in blood and effluent on&#xD;
      critically ill patients receiving CRRT in order to characterize drug pharmacokinetics and&#xD;
      optimize dosing strategies in patients on CRRT.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2017</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Influence of renal replacement therapy on drug exposure (AUC of plasma concentration levels)</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>Simultaneous samples will be taken from pre-filter, post-filter, and effluent sampling ports before dose administration, after the completion of the infusion or 1 hours post oral dose, and 6 additional time points post-infusion or post oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Influence of renal replacement therapy on drug clearance</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>Simultaneous samples will be taken from pre-filter, post-filter, and effluent sampling ports before dose administration, after the completion of the infusion or 1 hours post oral dose, and 6 additional time points post-infusion or post oral administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determination of drug specific sieving coefficient (SC)</measure>
    <time_frame>Single Dosing Interval - 12 hours</time_frame>
    <description>SC is a measure of a filter efficiency in clearing drugs and solute. SC will be calculated using pre-filter and effluent concentrations</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">18</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Renal Insufficiency</condition>
  <condition>Renal Failure</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>No study intervention</arm_group_label>
    <description>No study intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenytoin</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenobarbital</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ketamine</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>No study intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients undergoing CRRT who are also being treated with an antiepileptic drug&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Expected to be on CRRT and receive any of the following for more than 24 hrs&#xD;
&#xD;
          -  Expected to survive for more than 24 hrs&#xD;
&#xD;
          -  Achievement of steady state drug concentrations prior to study enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Age &lt; 18&#xD;
&#xD;
          -  Prisoner&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeraj Badjatia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Maryland, College Park</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 25, 2018</study_first_submitted>
  <study_first_submitted_qc>August 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Maryland, Baltimore</investigator_affiliation>
    <investigator_full_name>Neeraj Badjatia</investigator_full_name>
    <investigator_title>Professor of Neurology</investigator_title>
  </responsible_party>
  <keyword>Antiepileptics</keyword>
  <keyword>Continuous Renal Replacement Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Phenytoin</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Levetiracetam</mesh_term>
    <mesh_term>Valproic Acid</mesh_term>
    <mesh_term>Phenobarbital</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

